Gateways to clinical trials

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 29, Issue 9, 2007, Pages 625-655

  Bayes M ^a   Rabasseda, X ^b   Prous, J R ^b  

^a PROUS SCIENCE   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [3 [4,5 DIHYDRO 1 (4 METHYLBENZYL) 5 OXO 1H 1,2 4 TRIAZOL 3 YL]PROPYL]PHENOXY] 2 METHYLPROPIONIC ACID; 5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ALFACALCIDOL; ALISKIREN; ALUMINUM HYDROXIDE; AMLODIPINE; AMLODIPINE PLUS BENAZEPRIL; AMLODIPINE PLUS VALSARTAN; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; ARRY 520; ATENOLOL; ATORVASTATIN; AVE 0277; BOSENTAN; CP 751871; DESMOPRESSIN; DG 041; E 5555; EZETIMIBE; FALECALCITRIOL; FELODIPINE; GHRELIN; GS 7904L; GV 1001; HT 1001; HYDROCHLOROTHIAZIDE; MEM 1003; MM 093; MONOCLONAL ANTIBODY; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OCTREOTIDE; OGX 011; OLMESARTAN; PACLITAXEL; PASIREOTIDE; PEGVISOMANT; PRASTERONE; QAE 397; RAMIPRIL; RAPAMYCIN; REC 15 2615; SSR 244738; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; UNIPROST; VALSARTAN;

ACROMEGALY; ACUTE LYMPHOCYTIC LEUKEMIA; ADRENAL INSUFFICIENCY; ALZHEIMER DISEASE; ANEMIA; ARTICLE; ATAXIA; BILE DUCT CANCER; BLADDER CANCER; BLOOD DISEASE; BONE CANCER; BREAST CANCER; CARDIOVASCULAR DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COLORECTAL CANCER; CORONARY ARTERY DISEASE; CORONARY STENT; CROHN DISEASE; CUSHING SYNDROME; DEPRESSION; DRUG DOSE TITRATION; DYSLIPIDEMIA; DYSTONIA; ENDOCRINE DISEASE; GLAUCOMA; HEART INFARCTION; HEPATITIS; HEPATITIS B; HEPATITIS C; HUMAN; HYPERCHOLESTEROLEMIA; HYPERPARATHYROIDISM; HYPERTENSION; INSOMNIA; KIDNEY CARCINOMA; KIDNEY DISEASE; KIDNEY FAILURE; LIVER CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHATIC SYSTEM DISEASE; MELANOMA; MENTAL DISEASE; METABOLIC SYNDROME X; MOTOR DYSFUNCTION; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; NEOPLASM; NEUROENDOCRINE TUMOR; NEUROLOGIC DISEASE; NEUTROPENIA; NONHODGKIN LYMPHOMA; OBESITY; OVARY CANCER; OVERACTIVE BLADDER; PACLITAXEL ELUTING STENT; PANCREAS CANCER; PARKINSON DISEASE; PROSTATE CANCER; PULMONARY HYPERTENSION; RESPIRATORY TRACT DISEASE; SIROLIMUS ELUTING STENT; SKIN DISEASE; SUICIDE; THORAX DISEASE; THROMBOCYTOPENIC PURPURA; UNSPECIFIED SIDE EFFECT; URINARY TRACT DISEASE;

CLINICAL TRIALS AS TOPIC; HUMANS;

EID: 38749151025     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (204)

1. Nader, F., Bai, C., Terra, K. et al. Darbepoetin alfa and filgrastim for the management of anemia and neutropenia in chronic hepatitis C (CHC). Gastroenterology 2007, 132(4, Suppl. 2): Abst M1871.
2. Newland, A., Caulier, M.T., Kappers-Klunne, M. et al. An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br J Haematol 2006, 135(4): 547.
3. Weissman, N.J., Ellis, S.G., Grube, E. et al. Effect of the polymer-based, paclitaxel-eluting TAXUS Express stent on vascular tissue responses: A volumetric intravascular ultrasound integrated analysis from the TAXUS IV, V, and VI trials. Eur Heart J 2007, 28(13): 1574.
4. Rabijewski, M., Papierska, L., Zgliczynski, W. Dehydroepiandrosterone therapy in men with verified coronary heart disease: The effects on fibrinogen, plasminogen activator inhibitor-1 (PAI-1) and tissue plasminogen activator (tPA). Endocr Abstr 2007, 14: Abst P82.
5. Blagden, M.D., Chipperfield, R. Efficacy and safety of ezetimibe co-administered with atorvastatin in untreated patients with primary hypercholesterolaemia and coronary heart disease. Curr Med Res Opin 2007, 23(4): 767.
6. Kaneda, H., Saito, S., Miyashita, Y. et al. Comparison of sirolimus-eluting stents with bare metal stents in the treatment of coronary artery disease in dialysis patients: An angiographic analysis. Eur Heart J 2006, 27(Abstract Suppl.): Abst P3915.
7. Lee, S.R., Jeong, M.H., Kim, Y.J. et al. Early clinical results of 2 drug-eluting stents. Cypher and Taxus, in Korean patients with acute myocardial infarction. Am J Cardiol 2007, 99(8, Suppl.): Abst AS-44.
8. Daemen, J., Sianos, G., Garcia-Garcia, H.M. et al. Do sirolimus-eluting stents remain superior to bare metal stents in patients with acute myocardial infarction after 3 years of follow-up? Insights into the RESEARCH registry. Eur Heart J 2006, 27(Abstract Suppl.): Abst 4866.
9. Erdine, S., Ro, Y., Tse, H. et al. Multiple-risk intervention with single-pill amlodipine besylate/atorvastatin calcium therapy helps patients with diverse ethnicity attain recommended therapeutic goals for blood pressure and lipids (The GEMINI-AALA study). J Hypertens 2007, 25(Suppl. 2): Abst 7C.6.
10. Yarows, S.A., Oparil, S., Patel, S. et al. Suppression of the renin system with the oral direct renin inhibitor aliskiren alone and in combination with valsartan in patients with hypertension. J Hypertens 2007, 25(Suppl. 2): Abst P28.364.
11. Andersen, K., Weinberger, M.H., Egan, B. et al. Aliskiren-based therapy lowers blood pressure more effectively than ramipril-based therapy in patients with hypertension: A 6-month, randomized, double-blind trial. J Hypertens 2007, 25(Suppl. 2): Abst P40.291.
12. Oparil, S., Yarows, S.A., Patel, S. et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: A randomised, double-blind trial. Lancet 2007, 370(9583): 221.
13. Tissot, A.C., Maurer, P., Nussberger, J. et al. Vaccination against angiotensin II reduces day-time ambulatory blood pressure: Results of a randomized placebo-controlled phase Ila study with CYT006-AngQb. J Hypertens 2007, 25(Suppl. 2): Abst 4B.8.
14. Brachmann, J., Handrock, R., Klebs, S. Effective and safe reduction of blood pressure by the combination of amlodipine 5/ valsartan 160mg in hypertensive patients not controlled by amlodipine 5mg or felodipine 5 mg - The EXPRESS-M trial. J Hypertens 2007, 25(Suppl. 2): Abst P41.334.
15. Zannad, F., Fay, R. Blood pressure lowering efficacy of olmesartan relative to other angiotensin II receptor antagonists: An overview of randomized controlled studies. J Hypertens 2006, 24(Suppl. 4): Abst P1.2.
16. Chrysant, S., Xu, J., Dubiel, R. Secondary analysis of the distribution of blood pressure reductions in patients receiving olme sartan medoxomil and hydrochlorothiazide in a factorial-design study. J Hypertens 2007, 25(Suppl. 2): Abst P41.316.
17. Hazan, L., Kelfkens, Y., Rodriguez, O. et al. Olmesartan medoxomil safely treats hypertension in children and adolescents: Results of a blinded dose-ranging study. J Hypertens 2007, 25(Suppl. 2): Abst P25.299.
18. Grossman, E., Elkayam, A., Baron, T. et al. The efficacy of add-on olmesartan in uncontrolled hypertension. J Hypertens 2007, 25(Suppl. 2): Abst P24.270.
19. Ewald, S. et al. OLMEBEST-study: Reduction of blood pressure in the treatment of patients with mild to moderate essential hypertension-analysis of the randomised study period. J Hypertens 2007, 25(Suppl. 2): Abst P1.43.
20. Neutel, J., Kereiakes, D., Punzi, H. et al. Attainment of blood pressure goals in patients with stage 2 hypertension treated with olmesartan/hydrochlorothiazide or benazepril/amlodipine. J Hypertens 2007, 25(Suppl. 2): Abst P25.301.
21. Chrysant, S., Neutel, J., Dubiel, R. et al. Efficacy of olmesartan medoxomil, plus hydrochlorothiazide in patients stratified by race, gender, age, bmi, and isolated systolic hypertension. J Hypertens 2007, 25(Suppl. 2): Abst P41.318.
22. Seki, S., Mochizuki, S. Olmesartan attenuates inflammation in essential hypertensive patients. J Hypertens 2007, 25(Suppl. 2): Abst P30.392.
23. Chrysant, S., Neutel, J., Dubiel, R. et al. Efficacy of treating stage 2 systolic hypertension with olmesartan medoxomil and olmesartan medoxomil/hydrochlorothiazide in black and non-black patients. J Hypertens 2007, 25(Suppl. 2): Abst P25.303.
24. Izzo, J., Silfani, T., Dubiel, R. et al. Efficacy of treating stage 2 systolic hypertension with olmesartan medoxomil and olmesartan medoxomil/hydrochlorothiazide in elderly patients and patients with isolated systolic hypertension. J Hypertens 2007, 25(Suppl. 2): Abst P41.319.
25. Neutel, J., Chrysant, S., Dubiel, R. et al. Efficacy of treating stage 2 systolic hypertension with olmesartan medoxomil and olmesartan/ hydrochlorothiazide in patients stratified by gender and body mass index. J Hypertens 2007, 25(Suppl. 2): Abst P41.315.
26. Stumpe, K., Agabiti-Rosei, E., Scholze, J. et al. Effects of olmesartan and atenolol on carotid atherosclerosis: The multicenter olmesartan atherosclerosis regression evaluation (MORE) trial. J Hypertens 2007, 25(Suppl. 2): Abst 7C.3.
27. Trenkwalder, P., Schaetzl, R., Borbas, E. et al. Effective and safe reduction of pulse pressure by the combination of amlodipine 10/valsartan 160 in hypertensive patients not controlled by the combination of ramipril 5/felodipine 5 - A subanalysis of the EXPRESS-C trial. J Hypertens 2007, 25(Suppl. 2): Abst P24.263.
28. Trenkwalder, P., Schaetzl, R., Borbas, E. et al. Efficacy and safety of the combination of amlodipine 10/valsartan 160 in hypertensive patients not controlled by the combination of ramipril 5/felodipine 5 - The EXPRESS-C trial. J Hypertens 2007, 25(Suppl. 2): Abst P24.261.
29. Trenkwalder, P., Schaetzl, R., Borbas, E. et al. Efficacy and safety of amlodipine 10/valsartan 160mg in elderly patients with hypertension not controlled by ramipril 5/felodipine 5mg - A subanalysis of the EXPRESS-C trial. J Hypertens 2007, 25(Suppl. 2): Abst P24.260.
30. Trenkwalder, P., Schaetzl, R., Borbas, E. et al. Efficacy and safety of the combination of amlodipine 10/valsartan 160 in patients with hypertension and metabolic risk factors not controlled by the combination of ramipril 5/felodipine 5 - A subanalysis of the EXPRESS-C trial. J Hypertens 2007, 25(Suppl. 2): Abst P24.262.
31. Keefe, D.L., Andersen, K., Weinberger, M.H. et al. Blood pressure lowering effects persist following the last dose of long-term therapy with aliskiren, an oral direct renin inhibitor. J Hypertens 2007, 25(Suppl. 2): Abst P25.289.
32. Trenkwalder, P., Schaetzl, R., Borbas, E. et al. Efficacy and safety of amlodipine 10/valsartan 160 in overweight and obese patients with hypertension not controlled by ramipril 5/felodipine 5 - a subanalysis of the EXPRESS-C trial. J Hypertens 2007, 25(Suppl. 2): Abst P24.264.
33. Hirani, N., Manes, A., Romanazzi, S. et al. Effects of first-line bosentan therapy on survival in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2007, 175(Abstracts Issue): A397.
34. Voswinckel, R., Reichenberger, F., Kreckel, A. et al. Metered dose inhaler application of treprostinil for treatment of pulmonary hypertension. Am J Respir Crit Care Med 2007, 175(Abstracts Issue): A398.
35. Soto, F.J., Girotra, S., Cain, H. et al. Longer time interval between infusion site changes for subcutaneous (SQ) treprostinil (Remodulin) in patients with pulmonary hypertension (PH): Tolerance and safety. Am J Respir Crit Care Med 2007, 175(Abstracts Issue): A401.
36. Faraz, H.A., Shah, M.K., Qureshi, T.A. et al. Pulmonary hypertension in end-stage renal disease: Clinical and hemodynamic improvement with endothelin receptor antagonist bosentan. Chest 2006, 130(4, Suppl.): 304S.
37. Albarran, O.G., Lahera, M., Calvo, S. et al. Effects of olmesartan on insulin resistance and inflammatory cytokines in hypertensive patients with metabolic syndrome. J Hypertens 2007, 25(Suppl. 2): Abst P42.367.
38. Petersenn, S., Glusman, J., Unger, N. et al. The effects of pasireotide (SOM230) on glucose metabolism and growth hormone (GH) nadir during oral glucose tolerance test (OGTT) in 12 patients with acromegaly from a phase II study. Endocr Abstr 2007, 14: Abst P565.
39. Harris, P., D'Souza, G., Good, A. et al. A comparison between the efficacy and safety of pegvisomant to that of octreotide LAR in patients with acromegaly. Endocr Abstr 2007, 14: Abst P610.
40. Gasco, V., Mainolfi, A., De Giorgio, D. et al. Long-term pegvisomant treatment in acromegaly. Endocr Abstr 2007, 14: Abst P509.
41. Christiansen, J.J., Mehlsen, M., Geraldi, A.M. et al. Six months physiological DHEA substitution in female adrenal failure: Impact on qualify of life and sexual parameters. Endocr Abstr 2007, 14: Abst P475.
42. Miljic, D., Doknic, M., Pekic, S. et al. ACTH and Cortisol responses to ghrelin and DDAVP in patients with Cushing's disease (CD). Endocr Abstr 2007, 14: Abst P546.
43. Morii, H. Falecalcitriol in the treatment of hyperparathyroidism in hemodialysed patients. Osteoporos Int 2006, 17(Suppl. 1): Abst P349.
44. Pikilidou, M., Sarafidis, P., Konstas, A.G. et al. The effect of topical glaucoma therapy on 24h blood pressure monitoring in patients with and without essential hypertension. J Hypertens 2007, 25(Suppl. 2): Abst P40.294.
45. Rivera, E., Wahle, A., Joswick, T.R. et al. Lubiprostone, a novel type-2 chloride channel (Clc-2) activator, does not affect serum electrolyte balance in elderly and non-elderly patients with chronic idiopathic constipation. Gastroenterology 2007, 132(4, Suppl. 2): Abst S1188.
46. Johanson, J.F., Ueno, R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: A double-blind, placebo-controlled, dose-ranging study to evaluate efficacy and safety. Aliment Pharmacol Ther 2007, 25(11): 1351.
47. Loftus, E.V., Colombel, J.-F., Rutgeerts, P.J. et al. Short-term adalimumab therapy improves quality of life inpatients who had failed infliximab therapy: Results from the gain trial. Gastroenterology 2007, 132(4, Suppl. 2): Abst T1288.
48. Schreiber, S., Reinisch, W., Colombel, J.-F. et al. Early Crohn's disease shows high levels of remission to therapy with adalimumab: Sub-analysis of charm. Gastroenterology 2007, 132(4, Suppl. 2): Abst 985.
49. Thomsen, O.O., Screiber, S., Khaliq-kareemi, M. et al. Rapid onset of response and remission to subcutaneous certolizumab pegol and lack of influence of concomitant baseline medications in active Crohn's disease: Results from the open-label induction phase of the precise 2 study. Gastroenterology 2007, 132(4, Suppl. 2): Abst T1275.
50. Feagan, B.G., Sandborn, W.J., Brown, M. et al. Confirmed benefits of work productivity and daily activities of certolizumab pegol in Crohn's disease patients: Data from PRECiSE 1. Gastroenterology 2007, 132(4, Suppl. 2): Abst T1285.
51. Deltenre, P., Peyrin-Biroulet, L., Sandborn, W.J. et al. Efficacy of anti-TNF agents in luminal Crohn's disease: A meta-analysis. Gastroenterology 2007, 132(4, Suppl. 2): Abst 981.
52. Present, D., Feagan, B.G., Fedorak, R.N. et al. Natalizumab induces sustained response and remission in Crohn's patients after previous infliximab failure: Results from the ENCORE trial. Gastroenterology 2007, 132(4, Suppl. 2): Abst T1282.
53. Buchman, A.L., Kapikian, R., Demchyshyn, L.L. Teduglutide augments plasma citrulline, a marker of enterocyte mass in patients with Crohn's disease. Gastroenterology 2007, 132(4, Suppl. 2): Abst S1118.
54. Choung, R.S., Chitkara, D.K., Gonenne, J. et al. A randomized, double blind, placebo-controlled trial to evaluate the effects of asimadoline versus placebo on global gastric function and dyspepsia score in patients with functional dyspepsia. Gastroenterology 2007, 132(4, Suppl. 2): Abst M1154.
55. Vakil, N., Chey, W.D., Howden, C.W. et al. Tegaserod significantly improves moderate-severe dysmotility symptoms in patients with functional dyspepsia. Gastroenterology 2007, 132(4, Suppl. 2): Abst 643.
56. Talley, N.J., Chey, W.D., Vakil, N. et al. Baseline health-related quality of life is correlated with baseline symptom severity and is improved by tegaserod in patients with moderate to severe functional dyspepsia dysmotility symptoms. Gastroenterology 2007, 132(4, Suppl. 2): Abst S1870.
57. Szarka, L.A., Camilleri, M., Burton, D. et al. Efficacy of the peripheral kappa opioid agonist, asimadoline, on pain episodes of moderate severity in females with irritable bowel syndrome: A randomized, placebo-controlled, on-demand study. Gastroenterology 2007, 132(4, Suppl. 2): Abst W1213.
58. Lembo, A.J., Rosenbaum, D.P., Chey, W.D. et al. Safety and efficacy of crofelemer in patients with diarrhea predominant irritable bowel syndrome (d-IBS). Gastroenterology 2007, 132(4, Suppl. 2): Abst 944.
59. Hux, M., Maschio, M., Barbeau, M. et al. A cost-utility analysis of tegaserod in the treatment of constipation-predominant irritable bowel syndrome (IBS) based on the real-world trial, LOGIC. Gastroenterology 2007, 132(4, Suppl. 2): Abst W1217.
60. Pare, P., Gray, J.R., Lam, S. et al. Treatment of irritable bowel syndrome with tegaserod leads to significantly greater improvements in health-related quality of life, health status and work productivity as compared to controls in a usual care setting. Gastroenterology 2007, 132(4, Suppl. 2): Abst W1223.
61. Valenzuela, G.A. Tegaserod accelerates small bowel transit. Gastroenterology 2007, 132(4, Suppl. 2): Abst S1200.
62. Scavuzzo, F., Di Monda, G., Serino, D. et al. Thyroid abnormalities during treatment with PEGIFNalpha-2a and PEGIFNalpha-2b in patients affected by HCV-related chronic disease: A prospective randomized study. Endocr Abstr 2007, 14: Abst P323.
63. Micha, J.P., Goldstein, B.H., Birk, C.L. et al. Abraxane in the treatment of ovarian cancer: The absence of hypersensitivity reactions. Gynecol Oncol 2006, 100(2): 437.
64. Heathcote, E.J., Gane, E.J., Lai, C.L. et al. Salvage therapy with adefovir for virologic breakthrough in telbivudine-treated patients from the GLOBE study. Gastroenterology 2007, 132(4, Suppl. 2): Abst S1776.
65. Poynard, T., Ngo, Y., Marcellin, P. et al. Impact of adefovir dipivoxil on liver fibrosis and activity assessed with FibroTest-ActiTest in patients with chronic hepatitis B infection. J Hepatol 2007, 46(Suppl. 1): Abst 792.
66. Yoo, B.C., Kim, J.H., Chung, Y.H. et al. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 2007, 45(5): 1172.
67. Sherman, M., Yurdaydin, C., Sollano, J. et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006, 130(7): 2039.
68. Han, S.-H., Lai, C.L., Gane, E.J. et al. Telbivudine globe trial at year two: Efficacy, safety, and predictors of outcome in patients with chronic hepatitis B. Gastroenterology 2007, 132(4, Suppl. 2): Abst S1777.
69. Safadi, R., Xie, Q., Chen, Y. et al. A randomized trial of switching to telbivudine versus continued lamivudine in adults with chronic hepatitis B: Results of the primary analysis at week 24. J Hepatol 2007, 46(Suppl. 1): Abst 516.
70. Wang, Y., Jia, J., Hou, J. et al. A phase III comparative trial of telbivudine vs lamivudine in Chinese patients with chronic hepatitis B: Two years results. Gastroenterology 2007, 132(4, Suppl. 2): Abst S1768.
71. Sarrazin, C., Rouzier, R., Wagner, F. et al. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 2007, 132(4): 1270.
72. Cash, W.J., Patterson, K., Callender, M.E. et al. Does adjuvant therapy with erythropoietin and GCSF improve sustained virological response in patients receiving combination therapy with pegylated interferon and ribavirin for chronic hepatitis C? J Hepatol 2007, 46(Suppl. 1): Abst 578.
73. Savvidou, S., Goulis, J., Tsekoura, P. et al. Hepatic steatosis predicts outcome of chronic hepatitis C therapy with peg-interferon plus ribavirin, independently of genotype or BMI but in correlation to insulin resistance (HOMA-IR). J Hepatol 2007, 46(Suppl. 1): Abst 644.
74. Sanchez-Tapias, J.M., Ferenci, P., Diago, M. et al. How can we identify HCV genotype 1 patients who may benefit from an extended treatment duration with peg-interferon alpha-2a (40 kD) plus RBV? J Hepatol 2007, 46(Suppl. 1): Abst 641.
75. Bergk, A., Neumann, U.P., Van Boemmel, F. et al. Prediction of treatment response to 72 weeks of pegylated interferon alfa-2a plus ribavirin for chronic hepatitis C after liver transplantation. J Hepatol 2007, 46(Suppl. 1): Abst 575.
76. Klass, D.M., Hartmann, C., Braig, S. et al. Antiviral therapy with peginterferon alfa-2a and ribavirin does not reduce bone mineral density in patients with chronic viral hepatitis C genotype 1 infection. Gastroenterology 2007, 132(4, Suppl. 2): Abst S1234.
77. Scherzer, T.-M., Staufer, K., Steindl-Munda, P. et al. Early viral kinetics in patients with chronic hepatitis C genotype 2 or 3 treated with peg-interferon alpha-2a and ribavirin. J Hepatol 2007, 46(Suppl. 1): Abst 645.
78. Izumi, N., Hadziyannis, S.J., Lin, A. et al. Effect of ethnicity on higher virologic response rates in pts receiving peginterferon alfa-2a (40KD) and ribavirin for HCV genotype 1 infection. Gastroenterology 2007, 132(4, Suppl. 2): Abst M1868.
79. Marcellin, P., Hadziyannis, S.J., Berg, T. et al. Virological response at 4 and 12 weeks predict high rates of sustained virological response in genotype 1 patients treated with peginterferon alpha-2a (40 kD) plus ribavirin. J Hepatol 2007, 46(Suppl. 1): Abst 613.
80. Lagging, M., Pedersen, C., Buhl, M.R. et al. Comparison of peginterferon alpha-2a and ribavirin for 12 or 24 weeks in patients with HCV genotype 2/3: The NORDYNAMIC trial. J Hepatol 2007, 46(Suppl. 1): Abst 606.
81. Shiffman, M.L., Minola, E., Barange, K. et al. Characterisation of HCV genotype 2/3 patients without a rapid virological response (RVR): Optimising treatment by predicting slower responders to peg-interferon alpha-2a (Pegasys) plus ribavirin (Copegus). J Hepatol 2007, 46(Suppl. 1): Abst 648.
82. Deschenes, M., Yoshida, E., Peltekian, K. et al. Management of chronic hepatitis C in a diverse population with peginterferon alpha-2a and ribavirin: Final results of the Canadian Pegasys Expanded Access Program (EAF). J Hepatol 2007, 46(Suppl. 1): Abst 615.
83. Diago, M., Olveira, A., Solà, R. et al. Treatment of chronic he1patitis C genotype 1 with peginterferon- alpha2a (40 kDa) plus ribavirin under routine clinical practice in Spain: Early prediction of sustained virological response rate. Aliment Pharmacol Ther 2007, 25(8): 899.
84. Carrión, J.A., Navasa, M., García-Retortillo, M. et al. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: A randomized controlled study. Gastroenterology 2007, 132(5): 1746.
85. Palmer, M., Rubin, R., Rustgi, V. et al. Pre-dosing taribavirin prior to combination therapy with pegylated interferon alfa-2b versus standard combination dosing: 24-week interim results examining safety and viral kinetics. J Hepatol 2007, 46(Suppl. 1): Abst 626.
86. Palmer, M., Rubin, R.A., Rustgi, V.K. et al. Pre-dosing taribavirin prior to combination therapy with pegylated interferon alfa-2b versus standard combination dosing: 24-week interim results examining safety and viral kinetics. Gastroenterology 2007, 132(4, Suppl. 2): Abst M1805.
87. Gelderblom, H.C., Zeuzem, S., Weegink, C.J. et al. Neopterin and ALT as markers of inflammation in chronic hepatitis C patients during administration of the HCV NS3-4A protease inhibitor telaprevir (VX-950) in combination with peginterferon alfa 2a. J Hepatol 2007, 46(Suppl. 1): Abst 592.
88. Sporea, I., Popescu, A., Sirli, R. et al. Pegylated-interferon alpha 2a treatment for chronic hepatitis C in patients on chronic haemodialysis. World J Gastroenterol 2006, 12(26): 4191.
89. Peck-Radosavljevic, M., Boletis, J., Besisik, F. et al. Use of low-dose peg-interferon alpha-2a (40 kD) (Pegasys) to treat hepatitis C-infected end-stage renal disease patients undergoing haemodialysis: Interim results from a randomised study. J Hepatol 2007, 46(Suppl. 1): Abst 628.
90. Chan-Tack, K.M., Truffa, M.M., Struble, K.A. et al. Atazanavir- associated nephrolithiasis: Cases from the US Food and Drug Administration s Adverse Event Reporting System. AIDS 2007, 21(9): 1215.
91. Nunez, M., Romero, M., Ocampo, A. et al. Impact of anemia and zidovudine use on sustained virological response in a trial of pegylated interferon plus ribavirin in HIV/HCV-coinfected patients. J Hepatol 2007, 46(Suppl. 1): Abst 591.
92. Sode, J., Obel, N., Hallas, J. et al. Use of fluroquinolone and risk of Achilles tendon rupture: A population-based cohort study. Eur J Clin Pharmacol 2007, 63(5): 499.
93. Peyrani, P., Allen, M., Arnold, F. et al. The role of tigecycline in the treatment of infections due to extreme-drug resistant Acinetobacter baumanni: Report of 25 cases. Am J Respir Crit Care Med 2007, 175(Abstracts Issue): A328.
94. Ionita-Radu, F., Nuta, P., Fanea, F. et al. The value of peginterferon alpha-2a therapy for chronic C hepatitis in hemodialysed patients. J Hepatol 2007, 46(Suppl. 1): Abst 546.
95. Robert, S., Hamner, M.B., Ulmer, H.G. et al. Open-label trial of escitalopram in the treatment of posttraumatic stress disorder. J Clin Psychiatry 2006, 67(10): 1522.
96. Clammold, A., Sassone, J., Squitieri, F. et al. Aripiprazole in Huntington's disease: A first case report. Mov Disord 2007, 22(Suppl. 16): Abst 90.
97. Huurman, V.A., Decochez, K., Mathieu, C. et al. Therapy with the hsp60 peptide DiaPep277(TM) in C-peptide positive type 1 diabetes patients. Diabetes Metab Res Rev 2007, 23(4): 269.
98. Schloot, N.C., Meierhoff, G., Lengyel, C. et al. Effect of heat shock protein peptide DiaPep277 on ss-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: Two prospective, randomized, double-blind phase II trials. Diabetes Metab Res Rev 2007, 23(4): 276.
99. Lazar, L., Ofan, R., Weintrob, N. et al. Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: A randomised, double-blind phase II study. Diabetes Metab Res Rev 2007, 23(4): 286.
100. Raz, I., Avron, A., Tamir, M. et al. Treatment of new-onset type 1 diabetes with peptide DiaPep277(R) is safe and associated with preserved beta-cell function: Extension of a randomized, double-blind, phase II trial. Diabetes Metab Res Rev 2007, 23(4): 292.
101. Ferrer-Garcia, J.C., Merino-Torres, J.F., Segovia-Portoles, R. et al. One injection of detemir insulin administered before the lunch improves the metabolic control in type 1 diabetic patients. Endocr Abstr 2007, 14: Abst P37.
102. Bekris, L.M., Jensen, R.A., Lagerquist, E. et al. GAD65 autoantibody epitopes in adult patients with latent autoimmune diabetes following GAD65 vaccination. Diabet Med 2007, 24(5): 521.
103. Larsen, C.M., Faulenbach, M., Vaag, A. et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007, 356(15): 1517.
104. Garber, A.J., Schweizer, A., Baron, M.A. et al. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: A randomized, placebo-controlled study. Diabetes Obes Metab 2007, 9(2): 166.
105. Karl, D., Philis-Tsimikas, A., Darsow, T. et al. Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions, and weight. Diabetes Technol Ther 2007, 9(2): 191.
106. Silvani, G., Tartaglia, A., Acquati, S. et al. Insulin-sensitivity and glycaemic control improve on rosuvastatin (RSV) treatment in hypertriglyceridaemic type-2 diabetes (T2DM). Endocr Abstr 2007, 14: Abst P87.
107. Sorof, J., Berne, C., Siewert-Delle, A. et al. Effect of rosuvastatin or atorvastatin on urinary albumin excretion and renal function in type 2 diabetic patients. Diabetes Res Clin Pract 2006, 72(1): 81.
108. Nauck, M.A., Meininger, G., Sheng, D. et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: A randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007, 9(2): 194.
109. Brazg, R., Xu, L., Dalla Man, C. et al. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. Diabetes Obes Metab 2007, 9(2): 186.
110. Enns, G.M., Berry, S.A., Berry, G.T. et al. Survival after treatment with phenylacetate and benzoate for urea-cycle disorders. N Engl J Med 2007, 356(22): 2282.
111. Ott, C., Schlaich, M.P., Schmidt, B.M.W. et al. Rosuvastatin does not affect intraglomerular haemodynamics in patients with hypercholesterolemia. J Hypertens 2007, 25(Suppl. 2): Abst 2D.4.
112. Pollard, L.C., Murray, J., Moody, M. et al. A randomised, double-blind, placebo-controlled trial of a recombinant version of human alpha-fetoprotein (MM-093) in patients with active rheumatoid arthritis. Ann Rheum Dis 2007, 66(5): 687.
113. Maki-Petaja, K.M., Booth, A.D., Hall, F.C. et al. Ezetimibe and simvastatin reduce inflammation, disease activity, aortic stiffness and improve endothelial function in rheumatoid arthritis. Rheumatology (Oxford) 2007, 46(Suppl. 1): Abst 206.
114. Hawkey, C.J., Weinstein, W.M., Smalley, W.E. et al. Significant early reduction of ulcer complications with lumiracoxib compared with naproxen at day 8 of treatment in target. Gastroenterology 2007, 132(4, Suppl. 2): Abst M1920.
115. Willeke, P., Schotte, H., Schlueter, B. et al. Mycophenolate sodium in primary Sjogren's syndrome in patients refractory to other immunosuppressive agents. Ann Rheum Dis 2007, 66(Suppl. 2): Abst SAT0192.
116. Van der Heijde, D., Kivitz, A., Schiff, M.H. et al. Treatment with adalimumab reduces signs and symptoms and induces par tial remission in patients with ankylosing spondylitis (AS): 1-year results from ATLAS. Arthritis Rheum 2006, 54(9, Suppl.): Abst 2017.
117. Takada-Takatori, Y., Kume, T., Katsuki, H. et al. Mechanisms of the nicotinic receptor up-regulation induced by chronic treatment with donepezil and sensitization to donepezil-induced neuroprotection. J Pharmacol Sci 2007, 103(Suppl. 1): Abst E2H3-4.
118. Ramies, D.A., Sandler, A., Gary, R. et al. Bevacizumab: Analysis of clinical benefit in females across trials in colorectal cancer and non-small cell lung cancer. J Clin Oncol 2007, 25(18, Suppl.): Abst 7634.
119. Vora, A., Pai, V.R., Prabhash, K. et al. Cetuximab monotherapy in relapsed, refractory squamous cell carcinoma of head and neck; effective and safe modality of treatment with good quality of life: Preliminary experience from a single institute in India. Ann Oncol 2007, 18(Suppl. 9): Abst 61P.
120. Parikh, P., Vora, A., Prabhash, K. et al. Cetuximab monotherapy/combination chemotherapy in head and neck cancer: A single center experience of feasibility, efficacy and toxicity from India. Ann Oncol 2007, 18(Suppl. 9): Abst 63.
121. Senzer, N., Nemunaitis, J., Nemunaitis, M. et al. p53 therapy in a patient with Li-Fraumeni syndrome. Mol Cancer Ther 2007, 6(5): 1478.
122. Pollak, M.N., Lacy, M.Q., Lipton, A. et al. Pharmacodynamic properties of the anti-IGF-IR monoclonal antibody CP-751,871 in cancer patients. J Clin Oncol 2007, 25(18, Suppl.): Abst 3587.
123. Calvo, E., Malik, S., Siu, L. et al. Assessment of erlotinib pharmacodynamics in tumors and skin of patients with head and neck cancer. Ann Oncol 2007, 18(4): 761.
124. De Braud, F.G., Isambert, N., Curigliano, G. et al. A phase 1 dose escalation safety and pharmacokinetic (PK) study of SSR244738 administered as a one-hour intravenous (IV) infusion every 3 weeks in patients (pt) with refractory solid tumors. J Clin Oncol 2007, 25(18, Suppl.): Abst 2518.
125. Ciuleanu, T., Diculescu, M., Hoepffner, N.M. et al. A randomised phase II study of OSI-7904L versus 5-fluorouracil (FU)/leucovorin (LV) as first-line treatment inpatients with advanced biliary cancers. Invest New Drugs 2007, 25(4): 385.
126. Ray, E.R., Chatterton, K., Coull, N. et al. Hexylaminolevulinate photodynamic diagnosis (HPD) following intravesical Bacille Calmette Guerin (BCG) for superficial bladder cancer. BJU Int 2007, 99(Suppl. 4): Abst P21.
127. Dileo, P., Grosso, F., Casanova, M. et al. Trabectedin (T) in metastatic Ewing's family tumors (EFT) patients (pts) progressing after standard chemotherapy. J Clin Oncol 2007, 25(18, Suppl.): Abst 10040.
128. Chia, S., Dent, S., Ellard, S.L. et al. A phase II trial of a second generation antisense oligonucleotide (ASO) to clusterin (OGX-011) in combination with docetaxel in metastatic breast cancer (MBC): NCIC-CTG IND 164 trial. Proc Am Assoc Cancer Res (AACR) 2007, 48: Abst 3512.
129. Lin, N.U., Parker, L.M., Come, S.E. et al. Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: Unexpected incidence of hypersensitivity reactions. Invest New Drugs 2007, 25(4): 369.
130. Martin-Martorell, P., Rodriguez-Braun, E., Perez-Fidalgo, A. et al. Biweekly cetuximab and irinotecan for the treatment of refractory metastatic colorectal cancer. Ann Oncol 2007, 18(Suppl. 9): Abst 35PD.
131. Amato, R.J., Misellati, A., Khan, M. et al. A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC). J Clin Oncol 2006, 24(18, Suppl.): Abst 4530.
132. Verzoni, E., Bajetta, R., Procopio, G. et al. Safety and activity of sorafenib in advanced renal cell cancer. Ann Oncol 2007, 18(Suppl. 9): Abst 52PD.
133. Lilenbaum, R., Wang, X., Gu, L. et al. Phase II randomized trial of docetaxel plus cetuximab or bortezomib in patients with advanced NSCLC and performance status (PS) 2-CALGB 30402. J Clin Oncol 2007, 25(18, Suppl.): Abst 7595.
134. Cho, B., Im, C., Choi, H. et al. A phase II study of erlotinib treatment in advanced non-small lung cancer after failure of gefitinib: Is a clinical benefit still achievable? J Clin Oncol 2007, 25(18, Suppl.): Abst 7609.
135. Jimenez, U., Gurpide, A., Isla, D. et al. Erlotinib for first line treatment in unselected patients (p) with advanced or metastatic non-small cell lung carcinoma (NSCLC). J Clin Oncol 2007, 25(18, Suppl.): Abst 7639.
136. Riely, G.J., Rudin, C.M., Kris, M.G. et al. A randomized phase II trial comparing pulsed erlotinib before or after carboplatin and paclitaxel in patients with stage IIIB or IV non-small cell lung cancer. J Clin Oncol 2007, 25(18, Suppl.): Abst 7619.
137. Haura, E.B., Sommers, E., Becker, A. et al. Pilot phase II study of preoperative gefitinib in early stage non-small cell lung cancer with assessment of intratumor gefitinib levels and tumor target modulation. J Clin Oncol 2007, 25(18, Suppl.): Abst 7603.
138. Hirsch, F., Varella-Garcia, M., Cappuzzo, F. et al. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 2007, 18(4): 752.
139. Green, M.R., Miller, A.A., Wang, X.F. et al. Phase II randomized study of dose-dense docetaxel (Doc) and cisplatin (Cis) every two weeks with pegfilgrastim (Pfil) and darbepoetin alfa (Darb) with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (NSCLC): CAL. J Clin Oncol 2007, 25(18, Suppl.): Abst 7617.
140. Cannelli, N., Cassandrini, D., Bertini, E. et al. Novel mutations in CLN8 in Italian variant late infantile neuronal ceroid lipofuscinosis: Another genetic hit in the Mediterranean. Neurogenetics (Oxford) 2006, 7(2): 111.
141. Patel, J.D., Hensing, T.A., Villafor, V. et al. Pemetrexed and carboplatin plus bevacizumab for advanced non-squamous non-small cell lung cancer (NSCLC): Preliminary results. J Clin Oncol 2007, 25(18, Suppl.): Abst 7601.
142. Jotte, R.M., Reynolds, C.H., Conkling, P. et al. A randomized phase 2 trial of amrubicin compared to topotecan as second-line treatments in extensive disease small cell lung cancer (SCLC) sensitive to platinum-based first-line chemotherapy. J Clin Oncol 2007, 25(18, Suppl.): Abst 18064.
143. Bedikian, A.Y., Kim, K., Papadopoulos, N. et al. Preliminary results from a phase I/II study of the combination of lenalidomide and DTIC in patients with metastatic malignant melanoma previously untreated with systemic chemotherapy. J Clin Oncol 2007, 25(18, Suppl.): Abst 8533.
144. Perez, D.G., Suman, V., Amatruda, T. et al. Phase II trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma. J Clin Oncol 2007, 25(18, Suppl.): Abst 8560.
145. Gulec, S.A., Hostetter, R., Schwartzentruber, D. et al. Treatment of carcinoid tumor liver metastases with Y-90 microspheres: An effective cytoreduction for disease consolidation and symptom control. Ann Surg Oncol 2007, 14(2, Suppl.): Abst P204.
146. Yao, J.C., Phan, A.T., Chang, D.Z. et al. Phase II study of RAD001 (everolimus) and depot octreotide (Sandostatin LAR) in patients with advanced low grade neuroendocrine carcinoma (LGNET). J Clin Oncol 2006, 24(18, Suppl.): Abst 4042.
147. Gabra, H. Phase II study of DMXAA combined with carboplatin and paclitaxel in recurrent ovarian cancer. J Clin Oncol 2006, 24(18, Suppl.): Abst 5032.
148. Choudhury, A., Mosolits, S., Staff, C. et al. Treatment of advanced pancreatic cancer patients with a telomerase-peptide vaccine together with gemcitabine: A phase II clinical study. Proc Am Assoc Cancer Res (AACR) 2007, 48: Abst 1863.
149. Attard, G., Reid, A., Molife, R. et al. Abiraterone, an oral, irreversible, CYP450C17 enzyme inhibitor appears to have activity in post-docetaxel castration refractory prostate cancer (CRPC) patients (PTS). Ann Oncol 2007, 18(Suppl. 9): Abst 51PD.
150. Small, E.J., Fontana, J., Tannir, N. et al. A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer. BJU Int 2007, 100(4): 765.
151. Wayne, A., Findley, H.W., Lew, G. et al. Pre-clinical studies and phase I clinical trial of the anti-CD22 immunotoxin CAT-3888 (BL22) for pediatric acute lymphoblastic leukemia (ALL). J Clin Oncol 2007, 25(18, Suppl.): Abst 9560.
152. Mayer, J., Robak, T., Shotnicki, A. et al. Impact of prognostic factors on outcome in a phase III study comparing alemtuzumab to chiorambucil as first-line therapy for B-cell chronic lymphocytic leukemia (BCLL). J Clin Oncol 2007, 25(18, Suppl.): Abst 7035.
153. Ponomarova, O.V., Kavetsky, R.E. Treatment of indolent non-Hodgkin's lymphoma with liposomal doxorubicin. Ann Oncol 2007, 18(Suppl. 9): Abst 81.
154. Chanan-Khan, A.A., Kaufman, J.L., Mehta, J. et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: A multicenter retrospective study. Blood 2007, 109(6): 2604.
155. Loehle, M., Schrempf, W., Wolz, M. et al. Potassium channel blocker 4-aminopyridine is effective in late onset episodic ataxia type-2 (EA2) - A video case report. Mov Disord 2007, 22(Suppl. 16): Abst 49.
156. Ong, V.S., Deng, C., Murray, M. et al. Lack of hemodynamic effect of MEM 1003, a dihydropyridine calcium-channel blocker: An exposure-safety relationship assessment. Clin Pharmacol Ther 2007, 81(Suppl. 1): Abst PII-49.
157. Pappert, E.J. A multi-center, open-label, multiple-dose, dose-escalation, safety and tolerability study of botulinum toxin type-b in patients with cervical dystonia. Mov Disord 2007, 22(Suppl. 16): Abst 401.
158. McCall, V. et al. Two double-blind, placebo-controlled, 6-month trials of eszopiclone for insomnia: Pooled analysis by race/ethnicity. Sleep 2006, 29(Abst.): Abst 0733.
159. Trugman, J.M. Primary efficacy and safety of istradefylline (KW-6002) in levodopa-treated Parkinson's disease patients with motor response complications: Results of the KW-6002-US-013 study. Neurology 2007, 68(12, Suppl. 1): Abst P06.023.
160. Goodman, A., Schwid, S., Brown, T. et al. A phase 3, multi-center trial of oral, sustained-release fampridine (4-aminopyridine) in multiple sclerosis. Neurology 2007, 68(12, Suppl. 1): Abst S32.003.
161. Antel, P.J., Arbour, N., McCrea, E. et al. Effects of long term fingolimod (FTY720) therapy on circulating mononuclear cell populations in multiple sclerosis. Neurology 2007, 68(12, Suppl. 1): Abst S59.003.
162. Comi, G., Abramsky, O., Arbizu, T. et al. The effect of two doses of laquinimod on mri-monitored disease activity in patients with relapsing-remitting multiple sclerosis: A multi-center, randomized, double-blind, placebo-controlled study. Neurology 2007, 68(12, Suppl. 1): Abst S02.002.
163. Bozic, C., Belcher, G., Koojimans, M. et al. The safety of natalizumab in patients with relapsing multiple sclerosis: An update from touch and TYGRIS. Neurology 2007, 68(12, Suppl. 1): Abst P06.095.
164. Kasper, L.H., Everitt, D., Leist, T.P. et al. A phase I trial of an interleukin-12/23 monoclonal antibody in relapsing multiple sclerosis. Curr Med Res Opin 2006, 22(9): 1671.
165. Poewe, W., Oertel, W.H., Martignoni, E. et al. Results of rotigotine transdermal patch in advanced Parkinson's patients with motor fluctuations and in combination with levodopa: Results of the CLEOPATRA-PD trial. Mov Disord 2007, 22(Suppl. 16): Abst 828.
166. Giladi, N., Korczyn, A., Boroojerdi, B. Rotigotine transdermal patch in early stage Parkinson's disease: Results of a placebo-and ropinirole-controlled trial. Mov Disord 2007, 22(Suppl. 16): Abst 659.
167. Stocchi, F., Borgohain, R., Onofrj, M. et al. Safinamide, a new anti-Parkinson agent is effective and well-tolerated in early PD patients on a stable dose of a single DA-agonist: Results of a randomized, international, placebo-controlled, phase III trial. Neurology 2007, 68(12, Suppl. 1): Abst S20.001.
168. Nahab, F.B., Baines, S., Ippolito, D. et al. Long duration accelometry to assess efficacy of oral 1-octanol in patients with essential tremor. Mov Disord 2007, 22(Suppl. 16): Abst 971.
169. Jafar-Mohammadi, B., Walsh, T., Barry, J. et al. Pseudophaeochromocytoma presenting with catatonia - A novel observation. Endocr Abstr 2007, 14: Abst P471.
170. Callréus, T., Agerskov Andersen, U., Hallas, J. et al. Cardiovascular drugs and the risk of suicide: A nested case-control study. Eur J Clin Pharmacol 2007, 63(6): 591.
171. Chang, Y.-L., Lin, A.T.L., Chen, K.-K. Desmopressin increases urinary excretion of calcium in male patients with nocturnal polyuria. J Urol 2007, 177(4, Suppl.): Abst 1200.
172. Chappie, C., Van Kerrebroeck, P., Tubaro, A. et al. Efficacy of fesoterodine in patients with overactive bladder (OAB): Improvements in OAB symptoms and health-related quality of life (HRQL). J Urol 2007, 177(4, Suppl.): Abst 1188.
173. Khullar, V., Rovner, E.S., Dmochowski, R. et al. Dose response relationship of fesoterodine 4 mg vs 8 mg and onset of action in subjects with overactive bladder: Results from a pooled analysis of 2 randomized trials. Neurourol Urodyn 2007, 26(5): Abst 270.
174. Tubaro, A., Wang, J., Kopp, Z. et al. Improvements in health-related quality of life with fesoterodine in subjects with overactive bladder: Pooled data from two randomized controlled studies. Neurourol Urodyn 2007, 26(5): Abst 462.
175. Kato, M., Koshimo, Y., Yonemoto, C. et al. Anti-cholinergics tiotropium shows few micturition disturbance. Am J Respir Crit Care Med 2007, 175(Abstracts Issue): A130.
176. Pascoe, S.J., Knight, H. A comparison of the duration of action of two inhaled corticosteroids, budesonide and QAE397, by sequential AMP challenge in asthma. Am J Respir Crit Care Med 2007, 175(Abstracts Issue): A193.
177. Gauvreau, G.M., Boulet, L.P., Cote, J. et al. Effects of roflumilast on airway inflammation and function following allergen challenge in patients with allergic asthma. Am J Respir Crit Care Med 2007, 175(Abstracts Issue): A484.
178. Brindicci, C., Torre, O., Barnes, P.J. et al. Effect of aminoguanidine, an iNOS inhibitor, on exhaled NO and peroxynitrite concentrations in patients with COPD. Am J Respir Crit Care Med 2007, 175(Abstracts Issue): A395.
179. Kesten, S., Menjoge, S., Leimer, I. Pooled clinical trial analysis of the safety of tiotropium according to concomitant use of inhaled steroids. Am J Respir Crit Care Med 2007, 175(Abstracts Issue): A495.
180. Kang, Y.I., Choi, H.S., Choi, C.W. et al. The effect of tiotropium in adults with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 175(Abstracts Issue): A129.
181. Yamaguchi, Y., Teramoto, S., Yamamoto, H. et al. Decreased residual volume by tiotropium bromide inhalation augments diaphragmatic function and improves dyspnea during exercise in patients with COPD. Am J Respir Crit Care Med 2007, 175(Abstracts Issue): A132.
182. Teramoto, S., Yamamoto, H., Yamaguchi, Y. et al. The long-term effects of combination therapy with inhaled tiotropium bromide and transdermal tulobuterol path on pulmonary function and quality of life in patients with COPD. Am J Respir Crit Care Med 2007, 175(Abstracts Issue): A129.
183. Hatpin, D.M.G., Leimer, I., Groenke, L. Pooled analysis of tiotropium efficacy in patients not receiving maintenance therapy for COPD. Am J Respir Crit Care Med 2007, 175(Abstracts Issue): A128.
184. Hara, K., Kurashima, K., Tokunaga, D. et al. Single blind comparison of tiotropium and salmeterol plus fluticasone propionate of treatment in patients with chronic obstructive pulmonary disease (COPD). Am J Respir Crit Care Med 2007, 175(Abstracts Issue): A127.
185. Passeron, T., Lacour, J.P., Fontas, E. et al. Treatment of oral erosive lichen planus with 1% pimecrolimus cream: A double-blind, randomized, prospective trial with measurement of pimecrolimus levels in the blood. Arch Dermatol 2007, 143(4): 472.
186. Oskay, T., Kaya Sezer, H., Genç, C. et al. Pimecrolimus 1% cream in the treatment of vulvar lichen sclerosus in postmenopausal women. Int J Dermatol 2007, 46(5): 527.
187. Bilenchi, R., Pisani, C., Andreassi, A. et al. Topical calcineurin inhibitors in the management of anogenital lichen sclerosus unresponsive to ultra-potent corticosteroids: Our experience. J Invest Dermatol 2007, 127(Suppl. 1): Abst 270.
188. Toichi, E., Torres, G., McCormick, T.S. et al. An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis. J Immunol 2006, 177(7): 4917.
189. Gottlieb, A.B., Cooper, K.D., McCormick, T.S. et al. A phase 1, double-blind, placebo-controlled study evaluating single subcutaneous administrations of a human interleukin-12/23 monoclonal antibody in subjects with plaque psoriasis. Curr Med Res Opin 2007, 23(5): 1081.
190. Dubertret, L., Zalupca, L., Cristodoulo, T. et al. Once-daily rupatadine improves the symptoms of chronic idiopathic urticaria: A randomised, double-blind, placebo-controlled study. Eur J Dermatol 2007, 17(3): 223.
191. Williams, K.E., Reeves, K.R., Billing, C.B., Jr. et al. A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Curr Med Res Opin 2007, 23(4): 793.
192. Salomone, M.M., Kam, C.C., Saleh, K. et al. The use of extended release epidural morphine (Depodur) leads to decreased length of stay in patients undergoing total hip arthroplasty. Anesth Analg 2007, 104(2, Suppl.): Abst S-190.
193. Darras, F.S., Moss, V.J., Suh, H. et al. Prednisone-free renal transplant outcomes with campath induction in African-American recipients. J Urol 2007, 177(4, Suppl.): Abst 1814.
194. Riddell, A., Buttery, J.P., McVernon, J. et al. A randomized study comparing the safety and immunogenicity of a conjugate vaccine combination containing meningococcal group C and pneumococcal capsular polysaccharide- CRM(197) with a meningococcal group C conjugate vaccine in healthy infants: Challenge phase. Vaccine 2007, 25(19): 3906.
195. Zhang, W., Wu, J., Atkinson, S. et al. Effects of TAK-390MR on plasma gastrin levels in healthy adults. Clin Pharmacol Ther 2007, 81(Suppl. 1): Abst PI-44.
196. Vakily, M., Wu, J., Atkinson, S. Effect of single oral doses (90 and 300 mg) of TAK-390MR on QT intervals. Clin Pharmacol Ther 2007, 81(Suppl. 1): Abst PI-43.
197. Hermann, D., Wang, W., Van Ess, P. et al. Quantifying the effects of DG-041 on platelet aggregation in healthy volunteers. Clin Pharmacol Ther 2007, 81(Suppl. 1): Abst PIII-20.
198. Takeuchi, M., Kageyama, M., Kitamura, S. et al. Pharmacodynamics and safety of a novel protease activated receptor-1 antagonist E5555 for healthy volunteers. Eur Heart J 2007, 28(Suppl. 1): 14.
199. Braun, M., Eishoff, J.P., Andreas, J.O. et al. Lack of drug interactions between transdermal rotigotine and oral contraceptives. Mov Disord 2007, 22(Suppl. 16): Abst 879.
200. Farid, N.A., Harris, C.J., Abu-Raddad, E. et al. No clinically relevant changes in the exposure of lovastatin or pravastatin with concurrent administration of LY518674. Clin Pharmacol Ther 2007, 81 (Suppl. 1): Abst PIII-84.
201. Jones, M.R., Sealey, J.E., Laragh, J.H. Effects of angiotensin receptor blockers on ambulatory plasma renin activity in healthy, normal subjects during unrestricted sodium intake. Am J Hypertens 2007, 20(8): 907.
202. Rijneveld, J.M., Rad, M., Ter Kuile, M.M. et al. Safety, tolerability and pharmacokinetics of a single intravaginal dose of REC 15/2615, a topical alpha1-antagonist in healthy female volunteers. Clin Pharmacol Ther 2007, 81(Suppl. 1): Abst PII-55.
203. Geary, R., Yu, R., Bradley, J. et al. Lack of pharmacokinetic interactions of an antisense oligonucleotide, targeting human apoB, when coadministered with simvastatin & ezetimibe, in man. Atheroscler Suppl 2006, 7(3): Abst Th-P16:258.
204. Zhou, X.-J., Pietropaolo, K., Becker, M. et al. Absence of pharmacokinetic drug-drug interaction between telbivudine and tenofovir. Gastroenterology 2007, 132(4, Suppl. 2): Abst S1782.